Attached files
| file | filename |
|---|---|
| 8-K - 8-K - Blueprint Medicines Corp | bpmc_8kearnings11-102016.htm |
Exhibit 99.1
Blueprint Medicines Reports Third Quarter 2016 Financial Results
– Preliminary data from BLU-285 in systemic mastocytosis (SM) to be presented at 2016 ASH Annual Meeting –
– Preliminary data from BLU-285 in gastrointestinal stromal tumors (GIST) and BLU-554 in hepatocellular carcinoma (HCC) to be presented at EORTC-NCI-AACR Symposium –
CAMBRIDGE, Mass., November 10, 2016 – Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today reported financial results and provided a business update for the third quarter ended September 30, 2016.
“During the third quarter of 2016, we made significant progress on our pipeline and were pleased to announce our newest drug discovery program for the treatment of fibrolamellar carcinoma, a rare liver cancer with a recognized genomic driver. This program highlights how quickly our science is moving to identify new and promising kinase drug targets, and our continued commitment to patients who need new treatment options,” said Jeff Albers, Chief Executive Officer of Blueprint Medicines. “We believe the breadth of our pipeline is unique for a company of our size, and we are looking forward to announcing the early stage data on our three Phase 1 clinical trials before year-end.”
Corporate Highlights:
|
· |
Granted Fast Track Designation for BLU-285: In October 2016, the U.S. Food & Drug Administration (FDA) granted Fast Track designation to BLU-285 for the treatment of patients with unresectable or metastatic GIST that progressed following treatment with imatinib and a second tyrosine kinase inhibitor and for the treatment of patients with unresectable or metastatic GIST with the PDGFRα D842V mutation regardless of prior therapy. The FDA's Fast Track Drug Development Program is designed to expedite clinical development and submission of New Drug Applications (NDA) for medicines with the potential to treat serious or life-threatening conditions and address unmet medical needs. |
|
· |
Entered into a companion diagnostic collaboration with QIAGEN: In August 2016, Blueprint Medicines entered into a collaboration with QIAGEN Manchester Limited to develop and commercialize a companion diagnostic test to identify GIST patients with the PDGFRα D842V mutation for use with BLU-285. |
|
· |
Strengthened executive leadership team: In September 2016, Blueprint Medicines announced the appointment of Tracey McCain as Chief Legal Officer and Executive Vice President. |
Clinical Programs:
Blueprint Medicines’ lead drug candidates are BLU-285, a targeted inhibitor of both Exon 17 mutant KIT and D842V mutant PDGFRα, and BLU-554, a targeted inhibitor of the FGFR4 receptor. Enrollment continues to progress in Blueprint Medicines’ Phase 1 clinical trials for BLU-285 in unresectable, treatment-resistant GIST and advanced SM and BLU-554 in advanced HCC.
A poster presentation of preliminary data from the dose escalation portion of Blueprint Medicines’ Phase 1 clinical trial for BLU-554 in HCC will be presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Munich, Germany. The presentation, “First-in-Human Study of BLU-554, a Potent, Highly-Selective FGFR4 Inhibitor Designed for Hepatocellular Carcinoma (HCC) with FGFR4 Pathway Activation,” will be presented on November 29, 2016.
A late-breaking oral presentation of preliminary data from the dose escalation portion of Blueprint Medicines’ Phase 1 clinical trial for BLU-285 in GIST will also be presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. The presentation, “Preliminary Safety and Activity in a First-in-Human Phase 1 Study of BLU-285, a Potent, Highly-Selective Inhibitor of KIT and PDGFRα Activation Loop Mutants in Advanced Gastrointestinal Stromal Tumor (GIST),” will be presented on December 1, 2016.
An oral presentation of preliminary data from the dose escalation portion of Blueprint Medicines’ Phase 1 clinical trial for BLU-285 in advanced SM will be presented at the 2016 American Society of Hematology (ASH) Annual Meeting in San Diego, CA. The presentation, “Preliminary Safety and Activity in a Phase 1 Study of BLU-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (SM),” will be presented on December 4, 2016.
Third Quarter 2016 Financial Results:
|
· |
Cash Position: As of September 30, 2016, cash, cash equivalents, and investments were $152.5 million, as compared to $162.7 million as of December 31, 2015. This decrease was primarily related to cash used in operating activities, partially offset by the $45.0 million upfront payment received in March 2016 under Blueprint Medicines’ cancer immunotherapy collaboration with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, Roche). |
|
· |
Collaboration Revenue: Collaboration revenues were $6.2 million for the third quarter of 2016, as compared to $3.4 million for the third quarter of 2015. This increase was due to increased activity in Blueprint Medicines’ collaboration with Alexion and Blueprint Medicines entering into a collaboration with Roche in March 2016. |
|
· |
R&D Expenses: Research and development expenses were $18.2 million for the third quarter of 2016, as compared to $11.7 million for the same period in 2015. This increase was primarily attributable to increased manufacturing and clinical expenses associated with advancing BLU-285 and BLU-554 into clinical trials, continuing to build Blueprint Medicines’ platform and advance its discovery pipeline, and increased personnel-related expenses, including stock-based compensation expenses. |
|
· |
G&A Expenses: General and administrative expenses were $4.9 million for the third quarter of 2016, as compared to $4.2 million for the same period in 2015. This increase was primarily attributable to increased personnel-related expenses, including stock-based compensation expense. |
|
· |
Net Loss: Net loss was $16.8 million for the third quarter of 2016, or a basic and diluted net loss per share available to common stockholders of $0.62, as compared to a net loss of $12.6 million for the same period in 2015, or a basic and diluted net loss per share available to common stockholders of $0.47. |
Financial Guidance:
Blueprint Medicines expects that its cash, cash equivalents and investments balance will be at least $120 million at December 31, 2016. Blueprint Medicines expects that its existing cash, cash equivalents and investments will be sufficient to enable it to fund its operating expenses and capital expenditure requirements into early 2018.
Conference Call Information
Blueprint Medicines will host a live conference call and audio webcast today at 8:30 a.m. ET. The conference call may be accessed by dialing 855-728-4793 (domestic) or 503-343-6666 (international) and referring to conference ID 98230163. An audio webcast of the conference call will also be available in the Investors section of Blueprint Medicines’ website at http://ir.blueprintmedicines.com. The archived webcast will be available on Blueprint Medicines’ website approximately two hours after the conference call and will be available for 30 days following the call.
About Blueprint Medicines
Blueprint Medicines is developing a new generation of targeted and potent kinase medicines to improve the lives of patients with genomically defined diseases. The Company’s approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Blueprint Medicines is advancing three programs in clinical development for subsets of patients with gastrointestinal stromal tumors, hepatocellular carcinoma and systemic mastocytosis, as well as multiple programs in research and preclinical development. For more information, please visit www.blueprintmedicines.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans and timelines for the clinical development of BLU-285 and BLU-554; the timing of clinical data or proof of concept for preclinical and clinical programs, including, without limitation, the timing of preliminary clinical data for Blueprint Medicines’ Phase 1 clinical trials for BLU-285 and BLU-554; the potential benefits of Blueprint Medicines’ new drug discovery program targeting protein kinase cAMP-activated catalytic subunit alpha fusions for the treatment of fibrolamellar carcinoma; the potential benefits of Blueprint Medicines’ companion diagnostic collaboration with QIAGEN Manchester Limited (QIAGEN); expectations regarding Blueprint Medicines’ existing cash, cash equivalents and investments; and Blueprint Medicines’ strategy, business plans and focus. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are
subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to the delay of any current or planned clinical trials or the development of Blueprint Medicines’ drug product candidates, including BLU-285 and BLU-554; Blueprint Medicines’ advancement of multiple early-stage efforts; Blueprint Medicines’ ability to successfully demonstrate the efficacy and safety of its drug product candidates; the preclinical and clinical results for Blueprint Medicines’ drug product candidates, which may not support further development of such drug product candidates; and actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials; Blueprint Medicines’ ability to develop and commercialize companion diagnostics for its current and future drug candidates, including companion diagnostics for BLU-554 with Ventana Medical Systems, Inc. and for BLU-285 with QIAGEN; and the success of Blueprint Medicines’ rare genetic disease collaboration with Alexion Pharma Holding and its cancer immunotherapy collaboration with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Blueprint Medicines’ Quarterly Report on Form 10-Q for the quarter ended June 30, 2016, as filed with the Securities and Exchange Commission (SEC) on August 9, 2016, and other filings that Blueprint Medicines may make with the SEC in the future. Any forward-looking statements contained in this press release represent Blueprint Medicines’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Blueprint Medicines explicitly disclaims any obligation to update any forward-looking statements.
Blueprint Medicines Corporation
Selected Condensed Consolidated Balance Sheet Data
(in thousands)
(unaudited)
|
September 30, |
December 31, |
|||||
|
2016 |
2015 |
|||||
|
Cash, cash equivalents and investments |
$ |
152,544 |
$ |
162,707 | ||
|
Unbilled accounts receivable |
3,455 | 3,414 | ||||
|
Working capital (1) |
135,068 | 151,776 | ||||
|
Total assets |
167,849 | 178,898 | ||||
|
Deferred revenue |
51,347 | 13,640 | ||||
|
Term loan payable |
4,887 | 7,338 | ||||
|
Lease incentive obligation |
3,515 | 3,948 | ||||
|
Total stockholders’ equity |
97,710 | 143,979 | ||||
|
(1) Blueprint Medicines defines working capital as current assets less current liabilities. |
||||||
Blueprint Medicines Corporation
Condensed Consolidated Statements of Operations Data
(in thousands, except per share data)
(unaudited)
|
Three Months Ended |
Nine Months Ended |
|||||||||||
|
September 30, |
September 30, |
|||||||||||
|
2016 |
2015 |
2016 |
2015 |
|||||||||
|
Collaboration revenue |
$ |
6,160 |
$ |
3,426 |
$ |
20,081 |
$ |
6,765 | ||||
|
Operating expenses: |
||||||||||||
|
Research and development |
18,150 | 11,681 | 57,058 | 32,157 | ||||||||
|
General and administrative |
4,893 | 4,222 | 14,227 | 10,832 | ||||||||
|
Total operating expenses |
23,043 | 15,903 | 71,285 | 42,989 | ||||||||
|
Other income (expense): |
||||||||||||
|
Other income (expense), net |
158 | 6 | 350 | (435) | ||||||||
|
Interest expense |
(109) | (171) | (378) | (535) | ||||||||
|
Total other income (expense) |
49 | (165) | (28) | (970) | ||||||||
|
Net loss |
$ |
(16,834) |
$ |
(12,642) |
$ |
(51,232) |
$ |
(37,194) | ||||
|
Convertible preferred stock dividends |
— |
— |
— |
(3,153) | ||||||||
|
Net loss applicable to common stockholders |
$ |
(16,834) |
$ |
(12,642) |
$ |
(51,232) |
$ |
(40,347) | ||||
|
Net loss per share applicable to common stockholders — basic and diluted |
$ |
(0.62) |
$ |
(0.47) |
$ |
(1.89) |
$ |
(2.64) | ||||
|
Weighted-average number of common shares used in net loss per share applicable to common stockholders — basic and diluted |
27,251 | 26,835 | 27,170 | 15,298 | ||||||||
Contact:
Investor Relations:
Kristin Williams
Blueprint Medicines Corporation
617-714-6674
KWilliams@blueprintmedicines.com
Media Relations:
Rachel Hutman
W20 Group
301-801-5540
rhutman@wcgworld.com